2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

The current revolution in immuno-oncology is being driven by Antibody Drug Conjugates, Immune Checkpoint Inhibitors, Bispecific Antibodies and Cell Therapies. Clinical trials have showed that cancer patients can tolerate this immune-based treatment more effectively than conventional treatments like chemotherapy and radiotherapy. It’s clearly one of the hottest fields of Biopharma which has gained momentum in the past few years.

After our successful edition last year, we are coming up with the “2nd Annual MarketsandMarkets Next-Gen Immuno-Oncology Congress” on 19-20 September, Philadelphia, USA which will gather academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy.

Sessions:
• Targeted Antibodies and Combinations
• Pre-clinical & Translational Immuno-Oncology Developments
• New Antibody Formats
• New Immune Checkpoints for Immunotherapy
• Developments in CAR-T Cell Therapy and Vaccines
• New Antibodies Development and Tumor Microenvironment
• Personalized Immunotherapy and T-Cell

Key Highlights:
• Updates in development of monoclonal Abs and bispecific Abs
• Immune Checkpoint Inhibitors and Combinations
• Preclinical and Translational Immuno-Oncology Developments
• Biomarkers and Cancer Vaccines
• Next Gen CAR-T cell therapy, T-Cell Therapy
• Tumor

Why Attend:
• Find out new case studies of antibody projects in development
• Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
• Explore the latest platforms and technologies on the market for development
• Discuss the best tool for your research in immune-oncology
• Share your work and achievements with your industry peers in the Poster Session 

Additional details will be posted as soon as they are available.